Pursuit Vascular raises $2.1m

Pursuit Vascular has raised $2.1 million in a new round of debt financing, according to an SEC filing posted today. Maple Grove, Minn.-based Pursuit Vascular produces the ClearGueard HD end caps for hemodialysis catheters, designed to kill bacteria inside long-term hemodialysis catheters. The caps are designed with a chlorhexidine-coated rod that extends into the catheter hub to eliminate bacteria, and can be used in place of regular end caps for a single use. The device won FDA approval in late 2013. The $2.1 million is the maximum the company was looking for in the round, according to the SEC filing. Money in the round came from 31 unnamed sources, though the company has not yet said how it plans to spend funds in the round. Last April, the company said it reeled in more than $5.1 million through a new equity offering. Executives disclosed the new cash infusion in a regulatory filing, though specific investors are not mentioned. Pursuit said last February that it had secured $1.6 million in a debt and securities offering to 33 unnamed investors. The post Pursuit Vascular raises $2.1m appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blood Management Business/Financial News Catheters Pursuit Vascular Source Type: news

Related Links:

This study shows that YKL-40 increases with CKD stage and is negatively correlated with FMD measurements PMID: 30763987 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Conclusions: The repair of complex aortic aneurysms continues to be a challenge. Intraoperative bleeding greater than 1500 ml and the need of blood transfusion was associated with deterioration of postoperative renal function, affecting the 5-year survival of patients. PMID: 30768059 [PubMed - in process]
Source: Cirugia y Cirujanos - Category: Surgery Authors: Tags: Cir Cir Source Type: research
Forty million people in Western Europe have chronic kidney disease (CKD).1 The number of patients receiving renal replacement therapy (RRT) increased by 23% from 2006 to 2015.2,3 Males predominate on dialysis. The mean age of patients receiving dialysis is 61.3 years, and 19% are over 80 years.3 Hemodialysis and transplantation predominate, costing around €40,000 to €80,000 and €10,000 to €20,000 per patient per year, respectively.1 Overall, 2% of health expenditure is consumed by RRT for 0.1% of the population.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Policy Forum Source Type: research
On-line hemodiafiltration is an increasingly common alternative to chronic hemodialysis in some countries, based on the results of randomized controlled trials of post-dilution on-line hemodiafiltration. There are now more than 60,000 patients treated with on-line hemodialfiltration in Japan, over 95% of whom use predilution on-line hemodiafiltration; however, large-scale data on clinical outcomes with this modality are lacking. We created a propensity-matched cohort of 5,000 pairs of patients treated with conventional hemodialysis or predilution on-line hemodiafiltration, using the Japanese Society for Dialysis Therapy Re...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Investigation Source Type: research
Conclusion: HD presented a more adverse impact on oral health than PD, particularly periodontal disease and oral Candida colonization; however, this impact on oral health appears to be reduced or ameliorated when patients change from HD to PD therapy.
Source: Quintessence International - Category: Dentistry Source Type: research
Conditions:   Arteriovenous Graft Stenosis;   Arteriovenous Graft Thrombosis Intervention:   Diagnostic Test: Graft stenosis and thrombosis Sponsor:   Azienda Ospedaliera Universitaria Integrata Verona Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 15 February 2019Source: Medical Mycology Case ReportsAuthor(s): Rosângela L. Pinheiro, Regielly C.R. Cognialli, Rodolfo C. Barros, Tyane de A. Pinto, Mariana F.M. Cunha, Tony T. Tahan, Morgana F. Voidaleski, Renata R. Gomes, Guilherme N. Becker, Lucas V. Andrade, Flavio Queiroz-Telles, G. Sybren de Hoog, Renata R. Sakiyama, Vânia A. VicenteAbstractFungal peritonitis is frequent on peritoneal dialysis, with rare cases by Exophiala dermatitidis. A 25-month-old female admitted to the pediatric ICU with acute renal failure was submitted to peritoneal dialysis. After 10 days patien...
Source: Medical Mycology Case Reports - Category: Biology Source Type: research
Publication date: Available online 14 February 2019Source: American Journal of Kidney DiseasesAuthor(s): Michael Allon
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Fatigue is one of the most prevalent symptoms among haemodialysis (HD) patients. In order to design effective treatments it is crucial to understand the diurnal pattern of fatigue in this population.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Conclusions: Based upon anatomical and case studies, we have found that AV may join posterior aspect of superior vena cava at different directions and levels. Hence, this might explain why AV misplacement might occur whether an HDC is inserted from the LIJV or RIJV approach. By raising the awareness of this potential complication and how we may minimize it, we hope to reduce the future complication of AV misposition.Blood Purif
Source: Blood Purification - Category: Hematology Source Type: research
More News: Chlorhexidine | Dialysis | Hemodialysis | Medical Devices | Men